Clarus Therapeutics (CRXT) Tops Q4 EPS by 49c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Clarus (CRXT) PT Lowered to $8 at Needham & Company
March 31, 2022 7:00 AM EDTNeedham & Company analyst Serge Belanger lowered the price target on Clarus (NASDAQ: CRXT) to $8.00 (from $12.00) while maintaining a Buy rating.
... More